2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human hepatic cells

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

7

Peptides

1

MCE Kits

1

Inhibitory Antibodies

9

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1624
    Teduglutide
    2 Publications Verification

    ALX-0600

    		 Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide
  • HY-122515
    Fulvic Acid
    1 Publications Verification

    		 Others Metabolic Disease Inflammation/Immunology
    Fulvic Acid is a natural product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function. Fulvic Acid has the potential for researching chronic inflammatory diseases, including diabetes .
    Fulvic Acid
  • HY-19796
    Icomidocholic acid
    1 Publications Verification

    Aramchol; C20-FABAC

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
    Icomidocholic acid
  • HY-107582
    JW480

    		Ser/Thr Protease Calcium Channel PKC Cancer
    JW480 is a selective KIAA1363/AADACL1 inhibitor with oral activity, featuring IC50 values of 12 nM against human KIAA1363, 20 nM against mouse KIAA1363. JW480 blocks lipid deacetylase activity to restrain HAG metabolism and lowers retinyl ester hydrolase function in hepatic stellate cells. JW480 reduces MAGE lipid levels and inhibits migration, invasion, survival and tumor growth of prostate cancer cells. JW480 lowers PKCδ phosphorylation, facilitates HAGP accumulation, diminishes platelet aggregation, dense granule secretion and Ca 2+ flux, delays arterial thrombosis and prolongs tail bleeding time in rats. JW480 can be used for the study of prostate cancer and thrombosis .
    JW480
  • HY-N1990
    Gypenoside XLIX
    2 Publications Verification

    		 PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .
    Gypenoside XLIX
  • HY-107830
    Methyl cholate

    		Endogenous Metabolite Collagen Infection Metabolic Disease
    Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis .
    Methyl cholate
  • HY-135474
    KM91104
    2 Publications Verification

    		 ATP Synthase Toll-like Receptor (TLR) Others
    KM91104 is a cell-permeable V-ATPase a3-b2 inhibitor (IC50 = 2.3 µM). KM91104 reduces the metabolic activity, cell proliferation capacity and V-ATPase subunit protein expression levels of primary human hepatic stellate cells, increases intracellular ATP levels and decreases cytoplasmic pH. KM91104 reduces TLR4 expression on the surface of oligodendrocyte precursor cells, blocks the ENV-TLR4 interaction, and reverses oligodendrocyte myelination defects induced by ENV protein .
    KM91104
  • HY-168906
    BI-113823

    		Bradykinin Receptor PI3K Akt TNF Receptor ERK Neurological Disease Inflammation/Immunology
    BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension .
    BI-113823
  • HY-N0046
    Notoginsenoside Fe

    Notoginseng triterpenes; Ginsenoside Mb

    		 Apoptosis Src Neurological Disease Metabolic Disease Cancer
    Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma .
    Notoginsenoside Fe
  • HY-100590
    FPH1

    BRD6125

    		 Cytochrome P450 Others
    FPH1(BRD-6125) increases the number and activity of primary human hepatocytes in vitro and promotes the differentiation of iPS cells towards a hepatic lineage .
    FPH1
  • HY-W001084
    Methyl 4-hydroxyphenylacetate

    		Others Infection Cancer
    Methyl 4-hydroxyphenylacetate is a compound found in the marine fungus Penicillium oxalicum 0312F1. Methyl 4-hydroxyphenylacetate can be Methyl 4-hydroxyphenylacetate inhibits replication of tobacco mosaic virus (TMV) in Nicotiana tabacum leaf discs. Methyl 4-hydroxyphenylacetate shows inhibitory activity against proliferation of cancer cells. Methyl 4-hydroxyphenylacetate can be used for the researches of TMV infection and cancer .
    Methyl 4-hydroxyphenylacetate
  • HY-142026
    Vitisin A

    (+)-Vitisin A

    		 Caspase ERK NF-κB Influenza Virus PAK LDLR PPAR PCSK9 Androgen Receptor Keap1-Nrf2 Monoamine Oxidase Cholinesterase (ChE) IKK Wnt β-catenin Reactive Oxygen Species (ROS) Apoptosis Cuproptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC50 values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases .
    Vitisin A
  • HY-149406
    AMPK activator 12

    		AMPK Cancer
    AMPK activator 12 (compound 21) is a potent AMPK activator and GDF15 inducer. AMPK activator 12 increases GDF15 protein levels in human hepatic cells .
    AMPK activator 12
  • HY-Y1269D
    Ammonium chloride, for molecular biology

    Salmiac, for molecular biology

    		 TGF-beta/Smad Apoptosis Chloride Channel Neurological Disease Cancer
    Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases .
    Ammonium chloride, for molecular biology
  • HY-156065
    S217879

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related Metabolic Disease
    S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .
    S217879
  • HY-P1624S1
    Teduglutide-Leu(13C6,15N) sodium

    ALX-0600-Leu(13C6,15N) sodium

    		 Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide-Leu( 13C6, 15N) (ALX-0600-Leu( 13C6, 15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide-Leu(13C6,15N) sodium
  • HY-W719989
    γ-Carotene

    		Drug Intermediate Metabolic Disease
    γ-Carotene is a carotenoid found in Hippophae rhamnoides L. and peach palm fruits. γ-Carotene exhibits no significant inhibitory activity against self-activated hepatic stellate cells in vitro. γ-Carotene can be converted into retinol (Vitamin A) (HY-B1342) and can be used for the research of vitamin A deficiency [2].
    γ-Carotene
  • HY-P1624A
    Teduglutide TFA

    ALX-0600 TFA

    		 Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide TFA
  • HY-N12711
    Calycosin 7-O-xylosylglucoside

    		Others Others
    Calycosin 7-O-xylosylglucoside exhibits hepatoprotective efficacy in human hepatic cell HL-7702 through scavenging oxidative damage and antioxidant properties .
    Calycosin 7-O-xylosylglucoside
  • HY-121174
    Alaternin

    Catharticin

    		 NO Synthase CDK Tyrosinase Reactive Oxygen Species (ROS) Metabolic Disease
    Alaternin (Catharticin) is an anthraquinone compound with antioxidant and hepatoprotective activities. Alaternin has an inhibitory activity against hydroxyl radicals generated in a cell-free chemical system (FeSO4/H2O2) with an IC50 value of 3.05 μM. Alaternin exhibits hepatoprotective activity against Tacrine (HY-111338)-induced toxicity in human hepatic HepG2 cells with an EC50 value of 4.02 μM .
    Alaternin
  • HY-150596
    CT1-3

    		Apoptosis Bcl-2 Family JNK Cancer
    CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .
    CT1-3
  • HY-P1624S
    Teduglutide-Ala(13C3,15N) sodium

    ALX-0600-Ala(13C3,15N) sodium

    		 Isotope-Labeled Compounds Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide-Ala( 13C3, 15N) (ALX-0600-Ala( 13C3, 15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide-Ala(13C3,15N) sodium
  • HY-121698
    GW694481

    		Cytochrome P450 Inflammation/Immunology
    GW694481 is an ApoA1 upregulator with IC50 values of 2.1 μM for CYP2C9 inhibition and 17.0 μM for CYP3A4 inhibition. GW694481 upregulates ApoA1 expression in human hepatic cells.GW694481 can be used for the research of atherosclerosis .
    GW694481
  • HY-100590R
    FPH1 (Standard)

    BRD6125 (Standard)

    		 Cytochrome P450 Reference Standards Others
    FPH1 (Standard) is the analytical standard of FPH1 (HY-100590). This product is intended for research and analytical applications. FPH1(BRD-6125) increases the number and activity of primary human hepatocytes in vitro and promotes the differentiation of iPS cells towards a hepatic lineage .
    FPH1 (Standard)
  • HY-181392
    PROTAC EZH2 Degrader-35

    		PROTACs Histone Methyltransferase Cancer
    PROTAC EZH2 Degrader-35 (compound U3i (44)) is a PROTAC protein degrader targeting EZH2 with a human EZH2 Ka of 16.19 nM. PROTAC EZH2 Degrader-35 exhibits antiproliferative activity in triple-negative breast cancer cells and minimal cytotoxicity in normal human epithelial, hepatic, renal cells.PROTAC EZH2 Degrader-35 can be used for the research of triple-negative breast cancer .
    PROTAC EZH2 Degrader-35
  • HY-181486
    VDR agonist 5

    		VD/VDR Metabolic Disease
    VDR agonist 5 is an oral active VDR agonist. VDR agonist 5 activates VDR-mediated signaling to reduce liver fibrosis progression. VDR agonist 5 does not induce hypercalcemia. VDR agonist 5 can be used for the research of hepatic fibrosis .
    VDR agonist 5
  • HY-182287
    PRDX1-IN-4

    		Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Metabolic Disease
    PRDX1-IN-4 is a PRDX1 inhibitor with an IC50 of 122 nM against human targets and high subtype selectivity. PRDX1-IN-4 covalently binds to PRDX1 to promote ROS accumulation. PRDX1-IN-4 inhibits NLRP3 inflammasome activation, blocks hepatic stellate cell activation and reduces collagen deposition. PRDX1-IN-4 induces apoptosis in activated hepatic stellate cells. PRDX1-IN-4 has good safety profile, with no significant body weight loss or hepatotoxicity observed in mice at a dose of 20 mg/kg. PRDX1-IN-4 ameliorates CCl4-induced liver injury and liver fibrosis in mice at a dose of 1 mg/kg. PRDX1-IN-4 can be used for the research of liver fibrosis .
    PRDX1-IN-4
  • HY-181917
    Pantothenate kinase-IN-3

    		PANK Metabolic Disease
    Pantothenate kinase-IN-3 is an orally active PANK3-selective binder and CoA biosynthesis activator with a human PANK3 Ki of 9.1 nM, human PANK3 Ka of 1.8 nM, human PANK1β Ki of 113 nM, human PANK1β Ka of 23.4 nM, and oral effectiveness.Pantothenate kinase-IN-3 binds PANK3 via a water-mediated interaction between its sulfonamide NH and Gly193, elevates cellular, hepatic, and forebrain CoA levels, and shows improved metabolic stability in mouse and human microsomes.Pantothenate kinase-IN-3 has solubility properties favorable at pH 7.Pantothenate kinase-IN-3 can be used for the research of hepatic metabolic CoA deficiencies (acidemias) .
    Pantothenate kinase-IN-3
  • HY-181808
    HSF1/AMPK activator 1

    		AMPK TGF-beta/Smad Collagen Metabolic Disease
    HSF1/AMPK activator 1 is a compound that modulates the HSF1/AMPK axis and the TGF-β1/Smad signaling pathway. HSF1/AMPK activator 1 exhibits anti-hepatic fibrosis activity and metabolic stability. HSF1/AMPK activator 1 inhibits fibrosis formation and cell proliferation in activated hepatic stellate cells. HSF1/AMPK activator 1 alleviates liver injury and hepatic fibrosis symptoms in fibrotic mice. HSF1/AMPK activator 1 is applicable to research related to hepatic fibrosis .
    HSF1/AMPK activator 1
  • HY-181449
    CAY10729

    		Protein Arginine Deiminase Inflammation/Immunology
    CAY10729 (Compound 21) is a selective PAD2 inhibitor. CAY10729 inhibits neutrophil extracellular trap formation .
    CAY10729
  • HY-P11826
    T2 peptide-1

    		Collagen Metabolic Disease
    T2 peptide-1 is a linear peptide derived from Lumican degradation. T2 peptide-1 exhibits activity against endometrial adhesion progression and ability to inhibit the Lumican−Collagen I interaction. T2 peptide-1 can be used for the research of liver fibrosis .
    T2 peptide-1
  • HY-182356
    MTHFD1/2-IN-1

    		Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cancer
    MTHFD1/2-IN-1 is an orally active dual MTHFD1/MTHFD2 inhibitor, with IC50 values of 0.26 μM and 0.031 μM against human MTHFD1 and MTHFD2, respectively. MTHFD1/2-IN-1 blocks one-carbon metabolism by inhibiting the dehydrogenase activity of MTHFD1 as well as the dehydrogenase and cyclohydrolase activities of MTHFD2, thereby disrupting nucleotide biosynthesis and redox homeostasis in cancer cells. MTHFD1/2-IN-1 exhibits favorable Caco-2 permeability and hepatic microsomal metabolic stability. MTHFD1/2-IN-1 shows significant anti-leukemic activity, which not only reduces the viability of various leukemia cells but also inhibits tumor growth of acute myeloid leukemia (AML) in mouse models .
    MTHFD1/2-IN-1
  • HY-P11830
    UDA-6

    		Amylin Receptor Metabolic Disease
    UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
    UDA-6
  • HY-181643
    YOK24

    		MetAP Infection
    YOK24 is an orally active MetAP2 inhibitor and anti-amoebic agent. YOK24 binds covalently to MetAP2 and inhibits its peptidase activity, where MetAP2 is a protein essential for the proliferation of *Entamoeba histolytica*. YOK24 can be used in the research of amoebiasis .
    YOK24
  • HY-P11827
    C11 peptide-1

    		Collagen ERK TGF-beta/Smad Metabolic Disease
    C11 peptide-1 is an antifibrotic agent that binds directly to Collagen I. C11 peptide-1 physically disrupts Collagen I interaction with Lumican. C11 peptide-1 reduces inflammatory infiltration and inhibits the ERK1/2 and Smad2/3 signaling pathways. C11 peptide-1 can be used for the research of liver fibrosis .
    C11 peptide-1
  • HY-183337
    ZM734

    		NOD-like Receptor (NLR) Interleukin Related Inflammation/Immunology
    ZM734 is an orally active and selective NLRP3 inflammasome inhibitor. ZM734 inhibits the secretion of IL-1β. ZM734 alleviates pulmonary inflammation in a mouse model of acute lung injury. ZM734 can be used for the research of inflammatory diseases such as acute lung injury .
    ZM734
  • HY-182346
    FBPase-IN-7

    		FBPase Metabolic Disease
    FBPase-IN-7 is a fructose-1,6-bisphosphatase (FBPase) inhibitor with an IC50 of 0.75 μM. FBPase-IN-7 binds to a cryptic allosteric pocket of FBPase, induces conformational rearrangement of key residues, forms a hydrogen-bond network, and disrupts substrate catalysis. FBPase-IN-7 confirms cellular stabilizes HuFBPase in hepatic cells. FBPase-IN-7 has hypoglycemic activity. FBPase-IN-7 can be used for the research of type 2 diabetes .
    FBPase-IN-7
  • HY-182038
    TGF-β1/Smad3-IN-2

    		VD/VDR TGF-beta/Smad Collagen Hippo (MST) Metabolic Disease
    TGF-β1/Smad3-IN-2 is an orally active antifibrotic agent. TGF-β1/Smad3-IN-2 has high affinity for VDR and can inhibit the TGFβ/SMAD3 signaling pathway. TGF-β1/Smad3-IN-2 inhibits hepatic stellate cell activation, reduces extracellular matrix deposition, and alleviates liver fibrosis in a bile duct ligation mouse model. TGF-β1/Smad3-IN-2 can be used for the research of liver fibrosis .
    TGF-β1/Smad3-IN-2
  • HY-181792
    ZDZ-553

    		STAT Inflammation/Immunology
    ZDZ-553 is an orally active STAT1 inhibitor with an IC50 value of 0.87 μM. ZDZ-553 modulates STAT1 signaling to affect downstream lipid metabolism and inflammatory pathways. ZDZ-553 attenuates hepatic steatosis in NASH mouse models. ZDZ-553 reduces inflammatory responses in NASH mouse models. ZDZ-553 can be used for the research of nonalcoholic steatohepatitis .
    ZDZ-553
  • HY-P992072
    Anti-Human/Mouse CD95 Antibody (HFE7A)

    		Apoptosis Caspase Metabolic Disease
    Anti-Human/Mouse CD95 Antibody (HFE7A) is an antibody targeting human/mouse Fas (CD95), with a Kd of 1.6 nM in mice. Anti-Human/Mouse CD95 Antibody (HFE7A) modulates the Fas-mediated apoptotic signaling pathway without blocking the binding of Jo2 to Fas. Anti-Human/Mouse CD95 Antibody (HFE7A) inhibits Jo2-induced caspase activation, mitochondrial depolarization, hepatocyte death and apoptosis. Anti-Human/Mouse CD95 Antibody (HFE7A) protects BALB/c mice against Jo2-induced acute liver injury and reduces Jo2-associated elevation of serum transaminase levels. Anti-Human/Mouse CD95 Antibody (HFE7A) can be used in studies related to liver injury. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-Human/Mouse CD95 Antibody (HFE7A)
  • HY-182503
    GP515

    		Adenosine Kinase Others Inflammation/Immunology
    GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .
    GP515

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: